| アブストラクト | PURPOSE: There is an increase interest on the potential chemoprotective effect of selective phosphodiesterase 5 (PDE5) inhibitors. Several authors have shown in vivo the immune-mediated anti-tumor effect of these inhibitors on tumors arising from the digestive tract. OBJECTIVES: To test the potential effect of selective PDE5 inhibitors against colorectal cancer (CRC) onset previously observed. METHODS: We used data from The Health Improvement Network database and identified an established cohort of 200 000 new users of low-dose aspirin and a matched comparison cohort aged 40-84 years between 1 January 2000 and 31 December 2011. A follow-up to identify CRC cases was performed within an extensive validation exercise. Nested case-control analyses compared PDE5 inhibitors vs non-use on CRC risk were performed. RESULTS: Restricting to males (59.3% controls and 59.5% cases), no association was observed among current users of PDE5 inhibitors (1.05 [95% CI: 0.69-1.60]) and neither among recent (1.36 [95% CI: 0.81-2.28]) or past users (1.06 [95% CI: 0.72-1.58]). No duration response effect was found. CONCLUSIONS: Our results do not support an increased risk of CRC associated with the use of PDE5 inhibitors among men with erectile dysfunction. |
|---|
| ジャーナル名 | Pharmacoepidemiology and drug safety |
|---|
| Pubmed追加日 | 2020/4/9 |
|---|
| 投稿者 | Cea Soriano, Lucia; Garcia Rodriguez, Luis A |
|---|
| 組織名 | Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.;Department of Public Health and Maternal Child Health, Faculty of Medicine,;Complutense University of Madrid, Madrid, Spain. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32267029/ |
|---|
